GSK | ||
---|---|---|
OUTLOOK RATING 1..100 | 50 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 7 Undervalued | |
PROFIT vs RISK RATING 1..100 | 70 | |
SMR RATING 1..100 | 41 | |
PRICE GROWTH RATING 1..100 | 56 | |
P/E GROWTH RATING 1..100 | 29 | |
SEASONALITY SCORE 1..100 | n/a |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
DWMF | GSK | |
---|---|---|
RSI ODDS (%) | N/A | 4 days ago74% |
Stochastic ODDS (%) | 4 days ago60% | 4 days ago53% |
Momentum ODDS (%) | 4 days ago78% | 4 days ago52% |
MACD ODDS (%) | 4 days ago90% | 4 days ago67% |
TrendWeek ODDS (%) | 4 days ago73% | 4 days ago59% |
TrendMonth ODDS (%) | 4 days ago73% | 4 days ago51% |
Advances ODDS (%) | 5 days ago74% | 4 days ago58% |
Declines ODDS (%) | N/A | 6 days ago54% |
BollingerBands ODDS (%) | 4 days ago77% | 4 days ago64% |
Aroon ODDS (%) | 4 days ago71% | 4 days ago39% |
1 Day | |||
---|---|---|---|
ETFs / NAME | Price $ | Chg $ | Chg % |
FLEU | 31.09 | 0.17 | +0.54% |
Franklin FTSE Eurozone ETF | |||
SCHD | 26.88 | 0.13 | +0.49% |
Schwab US Dividend Equity ETF™ | |||
FFC | 16.34 | 0.06 | +0.37% |
Flaherty & Crumrine Preferred and Income Securities Fund | |||
FXZ | 57.69 | -0.05 | -0.09% |
First Trust Materials AlphaDEX® ETF | |||
ABLD | 28.20 | -0.18 | -0.65% |
Abacus FCF Real Assets Leaders ETF |
A.I.dvisor tells us that DWMF and SUN have been poorly correlated (+14% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that DWMF and SUN's prices will move in lockstep.
Ticker / NAME | Correlation To DWMF | 1D Price Change % | ||
---|---|---|---|---|
DWMF | 100% | N/A | ||
SUN - DWMF | 14% Poorly correlated | +1.42% | ||
TTE - DWMF | 10% Poorly correlated | +0.87% | ||
BNR - DWMF | 8% Poorly correlated | +6.23% | ||
SPOT - DWMF | 8% Poorly correlated | +2.79% | ||
GSK - DWMF | 8% Poorly correlated | +0.59% | ||
More |
A.I.dvisor indicates that over the last year, GSK has been loosely correlated with AZN. These tickers have moved in lockstep 62% of the time. This A.I.-generated data suggests there is some statistical probability that if GSK jumps, then AZN could also see price increases.